These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34879868)

  • 41. Iron Therapy in Inflammatory Bowel Disease.
    Kumar A; Brookes MJ
    Nutrients; 2020 Nov; 12(11):. PubMed ID: 33198376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patient Understanding of the Risks and Benefits of Biologic Therapies in Inflammatory Bowel Disease: Insights from a Large-scale Analysis of Social Media Platforms.
    Martinez B; Dailey F; Almario CV; Keller MS; Desai M; Dupuy T; Mosadeghi S; Whitman C; Lasch K; Ursos L; Spiegel BMR
    Inflamm Bowel Dis; 2017 Jul; 23(7):1057-1064. PubMed ID: 28410343
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extracorporeal lung support technologies - bridge to recovery and bridge to lung transplantation in adult patients: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(5):1-47. PubMed ID: 23074408
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals.
    Pittet VEH; Maillard MH; Simonson T; Fournier N; Rogler G; Michetti P;
    Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2050-2059.e1. PubMed ID: 30471455
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland.
    Mankinen P; Vihervaara V; Torvinen S; Martikainen J; Soini E
    J Med Econ; 2019 Apr; 22(4):328-335. PubMed ID: 30644325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of Anemia in Patients with Inflammatory Bowel Disease (IBD).
    Patel D; Trivedi C; Khan N
    Curr Treat Options Gastroenterol; 2018 Mar; 16(1):112-128. PubMed ID: 29404920
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quality improvement in healthcare for patients with inflammatory bowel disease.
    Georgy M; Negm Y; El-Matary W
    Transl Pediatr; 2019 Jan; 8(1):77-82. PubMed ID: 30881901
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany.
    Wilke T; Groth A; Long GH; Tatro AR; Sun D
    Clin Ther; 2020 Jan; 42(1):130-143.e3. PubMed ID: 31883702
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Factors that Influence Treatment and Non-treatment Decision Making Among Individuals with Inflammatory Bowel Disease: An Integrative Review.
    Kamp KJ; Brittain K
    Patient; 2018 Jun; 11(3):271-284. PubMed ID: 29313266
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting.
    Afzali A; Ogden K; Friedman ML; Chao J; Wang A
    J Med Econ; 2017 Apr; 20(4):409-422. PubMed ID: 28112566
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease.
    Vogelaar L; Spijker AV; van der Woude CJ
    Clin Exp Gastroenterol; 2009; 2():101-9. PubMed ID: 21694833
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.
    Perraudin C; Bourdin A; Spertini F; Berger J; Bugnon O
    J Clin Immunol; 2016 Jul; 36(5):502-10. PubMed ID: 27139500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Toward the development of a vibrant, super-aged society: The future of medicine and society in Japan.
    Iijima K; Arai H; Akishita M; Endo T; Ogasawara K; Kashihara N; Hayashi YK; Yumura W; Yokode M; Ouchi Y
    Geriatr Gerontol Int; 2021 Aug; 21(8):601-613. PubMed ID: 34212470
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 55. I am doing the best that I can!: Living with inflammatory bowel disease and/or irritable bowel syndrome (part II).
    Fletcher PC; Schneider MA; Van Ravenswaay V; Leon Z
    Clin Nurse Spec; 2008; 22(6):278-85. PubMed ID: 18955845
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers.
    Kariburyo MF; Xie L; Teeple A; Tan H; Ingham M
    Adv Ther; 2017 Jun; 34(6):1398-1410. PubMed ID: 28484953
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Fenster M; Ungaro RC; Hirten R; Gallinger Z; Cohen L; Atreja A; Mehandru S; Colombel JF; Cohen BL
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):257-258. PubMed ID: 30910602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
    Null K; Kumar V; Lissoos T; Luo M
    J Med Econ; 2018 Nov; 21(11):1102-1109. PubMed ID: 30101633
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness.
    McConnell J; Parvulescu-Codrea S; Behm B; Hill B; Dunkle E; Finke K; Snyder K; Tuskey A; Cox D; Woodward B
    World J Gastrointest Pharmacol Ther; 2012 Oct; 3(5):74-82. PubMed ID: 23515325
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.